Download our whitepaper,
"Optimizing Clinical Trial Design for Binge Eating Disorder: Overcoming Challenges and Improving Outcomes"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Binge Eating Disorder Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Binge Eating Disorder.
- Comprehensive Analysis of FDA-Approved Binge Eating Disorder Drugs.
- How Diagnostic Criteria for Binge Eating Disorder Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Binge Eating Disorder Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Binge Eating Disorder
Binge Eating Disorder (BED) is the most prevalent eating disorder globally, characterized by recurring episodes of excessive food consumption paired with feelings of a lack of control.
This disorder, formally recognized in the DSM-5 in 2013 and codified in the ICD-11 under 6B82, is distinct from other eating disorders due to the absence of compensatory behaviors post-binge. BED poses significant challenges, including increased risks of obesity, metabolic syndromes, and mental health conditions such as depression and anxiety.
At iNGENū, we are dedicated to advancing the understanding and treatment of Binge Eating Disorder. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.
BED affects approximately
3%
of the global population
Lifetime prevalence is
3.5%
in women compared to 2% in men
Global BED treatment market was valued at USD
$460m
in 2022
Our clinical team has over
120
years of combined clinical trial experience